14 results about "Bordetella sp" patented technology

The invention pertains to a mutant Bordetella OmpA polypeptide. A Bordetella comprising said mutant polypeptide has a high blebbing phenotype. Hence, the invention further pertains a method for producing OMVs, wherein the method comprises a step of culturing a population of Bordetella bacteria comprising a modified OmpA polypeptide, under conditions conductive for the production of OMVs. In addition, the invention pertains to OMVs produced by a Bordetella comprising a mutant OmpA polypeptide, and the use of such OMVs for the treatment and prevention of a Bordetella infection.

A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.

Chronic obstructive pulmonary disease is a major clinical challenge mostly due to cigarette smoke exposure and affects more than 200 million people. The inventors tested if exposure to the Bordetella pertussis BPZE1 strain could modulate outcomes of chronic exposure to cigarette smoke in mice. In particular, they showed in mice chronically exposed to cigarette smoke that preventive and / or curative vaccination using BPZE1 could limit the lung inflammation and strongly contribute to the prevention of lung function decline. BPZE1 vaccination modulated pulmonary antigen presenting cells (macrophages and dendritic cells) to switch the immune response, by decreasing the IL-17 inflammatory pathway involved in the pathology of COPD itself, and by favouring a tolerogenic response (IL-10). Together, the data show that vaccination with BPZE1 of mice chronically exposed to cigarette smoke limits the development of chronic obstructive pulmonary disease outcomes and thus represents an interesting therapy.

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

To provide a method for Bordetella fermentation and virulence factor production, especially PT production, for large-scale production, and in particular, to provide a method for medium adaptation performed before inoculation.SOLUTION: A method of producing a conditioned growth media comprising the steps of a. providing a sterile growth media; b. holding the sterile growth media at a temperature between about 28 to about 35 °C. for about 20 to 35 hours; and c. agitating and / or aerating the sterile growth media to generate a volumetric oxygen transfer coefficient (kLa) of about 10h-1 to about 130h-1, thereby providing a conditioned growth media.SELECTED DRAWING: Figure 1

Recent evidence accumulating over the last decade demonstrates that generation of CD4+ T cells is critical for sustained immunity against Bordetella pertussis. B. pertussis contains hundreds of antigens that are processed and presented on MHC Class II and recognized by CD4′T cells. The present disclosure relates to a vaccine comprising Bordetella pertussis antigen peptides to prevent infection of the Bordetella pertussis bacterium.

The present invention belongs to the technical field of environmental remediation microorganisms, and relates to an atrazine-degrading bacterium and its application. Aiming at the technical problems in the prior art that the atrazine-degrading bacterium has a low tolerance to atrazine, and the most suitable growth temperature and pH during degradation are not suitable for popularization and use, the present application provides an atrazine-degrading bacterium, Bordetella sp. strain BG-34, which is taxonomically named Bordetella sp. , and was deposited in the General Microbiology Center of the China Committee for Culture Collection of Microorganisms on November 9, 2022, with the deposit number of CGMCC No. 26091. It can tolerate atrazine with a concentration as high as 1500 mg / L, and is suitable for degrading atrazine in high-temperature seasons and low-latitude regions. The present application also provides an application of an atrazine-degrading bacterium. The most suitable growth temperature is 30-35 °C, the pH value is close to neutral, and it can grow and reproduce using atrazine as the sole nitrogen source, avoiding the inhibition of the growth of strain BG-34 by other nitrogen sources.

The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment with therapeutic agents that inhibit Bordetella holmesii. These methods are based on detecting Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.

The present invention relates to culture media and methods for cultivating Bordetella bacteria, particularly for producing vaccines. In particular, the inventors investigated the effects of temperature and alkaline earth metals and transition metals compositions on the growth and virulence factor production of B. pertussis and B. bronchiseptica. They found that both bacteria grew better and expressed more antigens when cultured in MILNEZ medium at 35°C, which mimics the nasal environment of healthy individuals. They also showed that B. pertussis genes were differentially regulated by these conditions. Therefore, the present invention provides a new culture medium that mimics growth conditions in the nose. The new medium includes a source of carbon, nitrogen, salts, alkaline earth metals and specific transitions metals at concentrations close to those in mammalian nasal fluid cavity. The invention aims to improve the growth of Bordetella bacteria for vaccine production.

A purification method is provided for removing impurities, such as GroEL, from a sample of outer membrane vesicles (OMV). For example, the method is applicable to OMV derived from Bordetella or Neisseria, such as Neisseria gonorrhoeae. Also provided are OMV purified by the methods described herein and immunogenic compositions, such as vaccines, containing the same.

This invention provides a method for producing a freeze-dried vaccine containing attenuated Bordetella bacteria. [Solution] A method for producing a freeze-dried vaccine includes the steps of: collecting Bordetella bacteria from a culture; mixing the collected Bordetella bacteria with a freeze-drying buffer; freeze-drying the mixture of Bordetella bacteria and the freeze-drying buffer, wherein the holding time between the collection step and the freeze-drying step is less than 48 hours, and the freeze-drying step includes a pre-crystallization holding step, in which the mixture of Bordetella bacteria and the freeze-drying buffer is held for 0.5 to 10 hours at a temperature 0.1 to 10°C higher than the crystallization temperature of the mixture before further cooling; and collecting the freeze-dried Bordetella bacteria.

The present invention includes compositions, including epitope megapools, and methods for detecting the presence of: a Bordetella or an immune response relevant to a Bordetella infection including T cells responsive to one or more Bordetella peptides or proteins comprising, consisting of, or consisting essentially of: one or more amino acid sequences, fusion proteins, a pool of 2 or more peptides, or polynucleotides that expression the amino acid sequences selected from those set forth in any one of Tables 1-20 (SEQ ID NOS: 1 to 2598). The invention further provides vaccines, diagnostics, therapies, and kits, comprising such proteins or peptides.

The latest evidence accumulated in the past ten years shows that the production of CD4 + T cells is crucial for sustained immunization against Bordetella pertussis. The Bordetella pertussis contains hundreds of antigens which are processed and presented on MHC class II, and are recognized by CD4 'T cells. The present disclosure relates to a vaccine comprising a Bordetella pertussis antigen peptide to prevent Bordetella pertussis bacterial infection.

To provide a vaccine for preventing pertussis capable of reducing asymptomatic Bordetella infection, in particular, asymptomatic B. pertussis infection (asymptomatic colonization).SOLUTION: A vaccine comprises a live attenuated Bordetella strain engineered to stably produce serotype 3 fimbriae (Fim3), where the live attenuated Bordetella strain retains the ability to colonize a mammalian subject's lungs and induce a protective immune response against Bordetella infection.SELECTED DRAWING: None